KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Receivables - Other (2019)

Palvella Therapeutics (PVLA) has disclosed Receivables - Other for 4 consecutive years, with $3.0 million as the latest value for Q2 2024.

  • On a quarterly basis, Receivables - Other changed N/A to $3.0 million in Q2 2024 year-over-year; TTM through Jun 2024 was $3.0 million, a N/A change, with the full-year FY2023 number at $3.1 million, up 579.87% from a year prior.
  • Receivables - Other was $3.0 million for Q2 2024 at Palvella Therapeutics, up from $2.3 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $3.1 million in Q4 2023 to a low of $462000.0 in Q4 2022.
  • A 3-year average of $2.2 million and a median of $2.7 million in 2024 define the central range for Receivables - Other.
  • Biggest YoY gain for Receivables - Other was 579.87% in 2023; the steepest drop was 579.87% in 2023.
  • Palvella Therapeutics' Receivables - Other stood at $462000.0 in 2022, then skyrocketed by 579.87% to $3.1 million in 2023, then fell by 2.93% to $3.0 million in 2024.
  • Per Business Quant, the three most recent readings for PVLA's Receivables - Other are $3.0 million (Q2 2024), $2.3 million (Q1 2024), and $3.1 million (Q4 2023).